MX2022006546A - Attenuated avian reovirus strains 94826 c140 and 96139 c140. - Google Patents

Attenuated avian reovirus strains 94826 c140 and 96139 c140.

Info

Publication number
MX2022006546A
MX2022006546A MX2022006546A MX2022006546A MX2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A
Authority
MX
Mexico
Prior art keywords
avian reovirus
tenosynovitis
progeny
derivatives
deposited
Prior art date
Application number
MX2022006546A
Other languages
Spanish (es)
Inventor
Holly S Sellers
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of MX2022006546A publication Critical patent/MX2022006546A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12061—Methods of inactivation or attenuation
    • C12N2720/12064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Attenuated isolates of avian reoviruses associated viral arthritis/tenosynovitis in poultry are presented, including avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077 and progeny or derivatives thereof and avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or compositions as vaccines to control of reovirus-induced viral arthritis/tenosynovitis in birds of the order <i>Galliformes</i> are also presented.
MX2022006546A 2019-12-02 2020-12-01 Attenuated avian reovirus strains 94826 c140 and 96139 c140. MX2022006546A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942426P 2019-12-02 2019-12-02
PCT/US2020/062651 WO2021113206A1 (en) 2019-12-02 2020-12-01 Attenuated avian reovirus strains 94826 c140 and 96139 c140

Publications (1)

Publication Number Publication Date
MX2022006546A true MX2022006546A (en) 2022-07-01

Family

ID=76221714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006546A MX2022006546A (en) 2019-12-02 2020-12-01 Attenuated avian reovirus strains 94826 c140 and 96139 c140.

Country Status (7)

Country Link
US (1) US20230000972A1 (en)
EP (1) EP4069289A4 (en)
JP (1) JP2023504225A (en)
CN (1) CN114828883A (en)
BR (1) BR112022010687A2 (en)
MX (1) MX2022006546A (en)
WO (1) WO2021113206A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478937B (en) * 2023-06-12 2023-08-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Gene III avian reovirus variant and application thereof in preparing vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232808A (en) * 2014-01-29 2016-12-14 乔治亚大学研究基金公司 Birds reovirus vaccine
CA3026241A1 (en) * 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections

Also Published As

Publication number Publication date
WO2021113206A1 (en) 2021-06-10
BR112022010687A2 (en) 2022-08-23
EP4069289A1 (en) 2022-10-12
EP4069289A4 (en) 2023-11-29
US20230000972A1 (en) 2023-01-05
CN114828883A (en) 2022-07-29
JP2023504225A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2019012100A (en) Seed endophytes across cultivars and species, associated compositions, and methods of use thereof.
NZ597182A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AR084441A1 (en) MUTANTS TYPE “SAND PAPER” (SAND PAPER) OF BACILLUS AND METHODS OF THE SAME USE TO IMPROVE VEGETABLE GROWTH, PROMOTE HEALTH OF PLANTS AND CONTROL DISEASES AND PESTS
MX2024008058A (en) Modified adenoviruses.
MX2022003435A (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l.
BRPI0518568A2 (en) Method for producing a replicative influenza virus particle without the use of helper virus, replicative influenza virus particle, Cell, composition, use of a composition, Method for generating immunological protection against infection of an individual with an influenza virus, , Nucleic acid
WO2018097603A3 (en) Middle east respiratory syndrome coronavirus s protein immunogenic composition and method for preparing same
CO2019010062A2 (en) Novel clostridium perfringens bacteriophage clo-pep-2 and its use to inhibit the proliferation of clostridium perfringens
MX2023001287A (en) Universal antigen-specific t cell banks and methods of making and using the same therapeutically.
MX2019006992A (en) Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning.
MX2022006546A (en) Attenuated avian reovirus strains 94826 c140 and 96139 c140.
UY36333A (en) SEED MATRICES THAT INCLUDE MICROORGANISMS OF BACILLUS SPP. TO BENEFIT THE GROWTH OF THE PLANT
MX2021008017A (en) Collagenase formulations and methods of producing the same.
MX2015016765A (en) Avian cells for improved virus production.
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
BR112021015638A2 (en) Methods, compositions containing bacillus-producing bacteria or preparations thereof
CN103272230B (en) Triple vaccine special for Muscovy duck
EA202191145A1 (en) VACCINE VIB 4/91 WITH HETEROLOGICAL SPINE PROTEIN
BR112022019207A2 (en) VACCINE COMPOSITIONS FOR CORONA VIRUSES AND METHODS OF THEIR USE
CO2018007607A2 (en) Compositions and methods of use of novel strains of lactobacillus fermentum
CO2020010533A2 (en) Novel salmonella heidelberg sal-hep-1 bacteriophage and its use to inhibit the growth of salmonella heidelberg bacteria
AR048429A1 (en) ISOLATED ANTIGENIC AND VACCINES OF INFECTIOUS BURSITIS VIRUS
Mor et al. Survival of turkey arthritis reovirus in poultry litter and drinking water
MX2017006638A (en) Methods and compositions for promoting lean body mass and minimize body fat gain and managing weight.
MX2023003198A (en) Attenuated isolate of infectious bronchitis virus strain dmv1639.